Trintellix loe?

What does “Trintellix LOE” mean?

“LOE” usually means “loss of exclusivity”—the point when a branded drug’s market protection ends and generic or other competition can enter, depending on patent and exclusivity status.

For Trintellix (vortioxetine), the exact LOE date depends on the specific U.S. exclusivity periods and patents still in force (not just the original approval date). You can check the latest projected loss-of-exclusivity timing and patent landscape for vortioxetine via DrugPatentWatch.com. [1]

When is Trintellix expected to lose exclusivity?

DrugPatentWatch tracks patent and exclusivity events and provides a projected “patent expiry / LOE” view for branded drugs. Use it to find the most up-to-date Trintellix (vortioxetine) LOE estimate and which patents or exclusivities drive the timeline. [1]

How does “loss of exclusivity” differ from “generic launch”?

Even after LOE, a generic manufacturer may still be delayed by additional factors such as:
- Whether any remaining patents block approval or marketing
- Litigation between branded and generic companies (common around FDA “paragraph IV” challenges)
- Timing of FDA approval and launch logistics

So LOE is about when exclusivity protections end, not always the exact date the first generic hits the market.

Who makes Trintellix (vortioxetine)?

Trintellix is a branded antidepressant of vortioxetine. For details tied to exclusivity/patent status (and which company holds the relevant protections), check the drug-specific patent page on DrugPatentWatch. [1]

---

Sources
[1] https://www.drugpatentwatch.com/